


Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

## CLAIM LISTING

1. (Currently amended) A compound of formula I




formula I

wherein

R<sup>1</sup> is hydrogen or C<sub>1-6</sub>-alkyl;

R<sup>2</sup> is hydrogen or C<sub>1-6</sub>-alkyl;

L is



wherein R<sup>4</sup> is hydrogen or C<sub>1-6</sub> alkyl;

p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 1;

the sum q + r + s + t + u is 0, 1, 2, 3, or 4;

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Q is  $>N-R^{13}$  or




wherein o is 0, 1 or 2;

T is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{14}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

$R^{14}$  is hydrogen, aryl or hetaryl;

or L is



p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 0 or 1;

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$R^9$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl;

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

Q is  $>\text{N-R}^{13}$  or




wherein  $o$  is 0, 1 or 2;

T is  $-\text{N}(\text{R}^{15})(\text{R}^{16})$  or hydroxyl;

$\text{R}^{13}$ ,  $\text{R}^{15}$ , and  $\text{R}^{16}$  are independently from each other hydrogen or  $\text{C}_{1-6}$  alkyl;

$\text{R}^{14}$  is hydrogen, aryl or hetaryl;

G is  $-\text{O}-(\text{CH}_2)_k-\text{R}^{17}$ ,




wherein  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$  and  $\text{R}^{21}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $\text{C}_{1-6}$ -alkyl or  $\text{C}_{1-6}$ -alkoxy;

$k$  is 0, 1 or 2;

J is  $-\text{O}-(\text{CH}_2)_l-\text{R}^{22}$ ,

Attorney Docket No. 5573.210-US  
 Pcschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999



wherein  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$  and  $R^{26}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy;

l is 0, 1 or 2;

a is 0, 1, or 2;

b is 0, 1, or 2;

c is 0, 1, or 2;

d is 0 or 1;

e is 0, 1, 2, or 3;

f is 0 or 1;

$R^5$  is hydrogen or  $C_{1-6}$ -alkyl optionally substituted with one or more hydroxyl, aryl or hetaryl;

$R^6$  and  $R^7$  are independently from each other hydrogen or  $C_{1-6}$ -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

$R^8$  is hydrogen or  $C_{1-6}$ -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

$R^6$  and  $R^7$  or  $R^6$  and  $R^8$  or  $R^7$  and  $R^8$  may optionally form  $-(CH_2)_i-U-(CH_2)_j-$ , wherein i and j independently from each other are 1, 2 or 3 and U is -O-, -S-, or a valence bond;

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

M is arylene, hetarylene, -O-, -S- or  $-\text{CR}^{27}=\text{CR}^{28}-$ ;


$\text{R}^{27}$  and  $\text{R}^{28}$  are independently from each other hydrogen or  $\text{C}_{1-6}$ -alkyl, optionally substituted with one or more aryl or hetaryl;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1 wherein  $\text{R}^1$  is  $\text{C}_{1-6}$ -alkyl.

3. (Original) The compound of claim 1 wherein  $\text{R}^2$  is  $\text{C}_{1-6}$ -alkyl.

4. (Currently amended) The compound of claim 1 wherein L is



wherein  $\text{R}^4$  is hydrogen or  $\text{C}_{1-6}$  alkyl;

p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 1;

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ , and  $\text{R}^{12}$  are independently from each other hydrogen or  $\text{C}_{1-6}$  alkyl;

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

Q is  $>\text{N-R}^{13}$  or




wherein o is 0, 1 or 2;

T is  $-\text{N}(\text{R}^{15})(\text{R}^{16})$  or hydroxyl;

$\text{R}^{13}$ ,  $\text{R}^{15}$ , and  $\text{R}^{16}$  are independently from each other hydrogen or  $\text{C}_{1-6}$  alkyl; and

$\text{R}^{14}$  is hydrogen, aryl or hetaryl.

5. (Original) The compound of claim 1 wherein L is



wherein q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 0 or 1;

the sum  $q + r + s + t + u$  is 0, 1, 2, 3, or 4;

$\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$ , and  $\text{R}^{12}$  are independently from each other hydrogen or  $\text{C}_{1-6}$  alkyl;

Q is  $>\text{N-R}^{13}$  or

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999




wherein  $o$  is 0, 1 or 2;

$T$  is  $-N(R^{15})(R^{16})$  or hydroxyl;

$R^{13}$ ,  $R^{15}$ , and  $R^{16}$  are independently from each other hydrogen or  $C_{1-6}$  alkyl; and


$R^{14}$  is hydrogen, aryl or hetaryl.

6. (Original) The compound of claim 1 wherein  $G$  is



wherein  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$  and  $R^{21}$  independently from each other are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy.

7. (Original) The compound of claim 1 wherein  $J$  is



wherein  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$  and  $R^{26}$  independently are hydrogen, halogen, aryl, hetaryl,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -alkoxy.

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

8. (Original) The compound of claim 1 wherein M is arylene or  $-\text{CR}^{27}=\text{CR}^{28}-$ , wherein  $\text{R}^{27}$  and  $\text{R}^{28}$  independently are hydrogen or  $\text{C}_{1-6}$ -alkyl, optionally substituted with aryl or hetaryl.


9. (Original) The compound of claim 1 wherein  $\text{R}^6$  and  $\text{R}^7$  independently from each other are hydrogen or  $\text{C}_{1-6}$ -alkyl.

10. (Original) The compound of claim 1 wherein  $\text{R}^6$  and  $\text{R}^7$  form  $-(\text{CH}_2)_i-\text{U}-(\text{CH}_2)_j-$ , wherein i and j independently from each other are 1, 2 or 3 and U is  $-\text{O}-$ ,  $-\text{S}-$ , or a valence bond.

11. (Original) The compound of claim 1 wherein  $\text{R}^8$  is hydrogen or  $\text{C}_{1-6}$ -alkyl.

12. (Previously presented) The compound of claim 1 selected from


(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

N-((1R)-1-{N-[(1R)-1-Benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methyl-3-((methylamino)methyl)benzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-[(1R)-1-(N-methyl-N-((1R)-1-[N-methyl-N-(1-methylpiperidin-4-yl)carbamoyl]-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl]amide


Attorney Docket No. 5573.210-US  
 Pcschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999



3-Aminomethyl-N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylbenzamide



(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 3573.210-US


Peschke et al.

Serial No. 09/356,313 Filed July 16, 1999

(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide




3-Aminomethyl-N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)benzamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide


Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
Peschke et al.  
Serial No. 09/356,313 Filed July 16, 1999

(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-(N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999




(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide



Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-(N-((1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-((1R)-1-benzyl-2-(4-hydroxy-4-(2-thienyl)piperidin-1-yl)-2-oxoethyl)-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide


Attorney Docket No. 5573.210-US

Peschke et al.


Serial No. 09/356,313 Filed July 16, 1999



(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(3-hydroxycyclohexylcarbonyl)-2-phenylethyl]-N-methylcarbonyl}-2-(2-naphthyl)ethyl)-N-methylamide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbonyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US


Peschke et al.

Serial No. 09/356,313 Filed July 16, 1999


(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-(2-thienyl)methyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-(2-thienyl)methyl]ethyl}-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-(2-thienyl)methyl]ethyl}-N-methylcarbamoyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US  
 Peschke et al.  
 Serial No. 09/356,313 Filed July 16, 1999

(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(1R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-[(2-thienyl)methyl]ethyl]-N-methylcarbamoyl}ethyl)-N-methylamide




(2E)-5-Methyl-5-(methylamino)hex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid ((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)amide, or

Attorney Docket No. 5573.210-US  
Peschke et al.  
Serial No. 09/356,313 Filed July 16, 1999



and pharmaceutically acceptable salts thereof.

13. (Original) A method of treating growth retardation in connection with asthma, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
14. (Original) The method of claim 13, wherein the compound is a growth hormone secretagogue.
15. (Previously presented) A composition comprising, as an active ingredient, a compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.
16. (Original) A method of stimulating the release of growth hormone from the pituitary of a mammal, the method comprising administering to the mammal an effective amount of a compound of claim 1 or a composition of claim 15.
17. (Original) A method of treating growth retardation in connection with juvenile rheumatic arthritis or cystic fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
18. (Cancelled)